Management of bipolar I depression: clinical utility of lurasidone

References

• AltshulerLLKupkaRWHellemannGGender and depressive symptoms in 711 patients with bipolar disorder evaluated prospectively in the Stanley Foundation bipolar treatment outcome networkAm J Psychiatry2010167670871520231325
   PubMed Web of Science ®Google Scholar
• JuddLLAkiskalHSSchettlerPJThe long-term natural history of the weekly symptomatic status of bipolar I disorderArch Gen Psychiatry200259653053712044195
   PubMed Web of Science ®Google Scholar
• JuddLLAkiskalHSSchettlerPJA prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorderArch Gen Psychiatry200360326126912622659
   PubMed Web of Science ®Google Scholar
• PostRMLeverichGSNolenWAA re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar NetworkBipolar Disord20035639640614636363
   PubMed Web of Science ®Google Scholar
• AltshulerLLPostRMBlackDOSubsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: results of a large, multisite studyJ Clin Psychiatry200667101551156017107246
   PubMed Web of Science ®Google Scholar
• GoldsteinBIHerrmannNShulmanKIComorbidity in bipolar disorder among the elderly: results from an epidemiological community sampleAm J Psychiatry2006163231932116449489
   PubMed Web of Science ®Google Scholar
• McElroySLKeckPEJrMetabolic syndrome in bipolar disorder: a review with a focus on bipolar depressionJ Clin Psychiatry2014751466124502861
   PubMed Web of Science ®Google Scholar
• RezaeitalabFMoharrariFSaberiSAsadpourHRezaeetalabFThe correlation of anxiety and depression with obstructive sleep apnea syndromeJ Res Med Sci201419320521024949026
   PubMed Web of Science ®Google Scholar
• SaunamäkiTJehkonenMDepression and anxiety in obstructive sleep apnea syndrome: a reviewActa Neurol Scand2007116527728817854419
   PubMed Web of Science ®Google Scholar
• PostRMAltshulerLLLeverichGSMore medical comorbidities in patients with bipolar disorder from the United States than from the Netherlands and GermanyJ Nerv Ment Dis2014202426527024647213
   PubMed Web of Science ®Google Scholar
• SierraPCámaraRTobellaHLivianosLWhat is the real significance and management of major thyroid disorders in bipolar patients?Rev Psiquiatr Salud Ment201472889524462913
   PubMed Web of Science ®Google Scholar
• WilliamsMDShahNDWagieAEWoodDLFryeMADirect costs of bipolar disorder versus other chronic conditions: an employer-based health plan analysisPsychiatr Serv20116291073107821885587
   PubMed Web of Science ®Google Scholar
• CascadeEFReitesJKalaliAHGhaemiNAntidepressants in bipolar disorderPsychiatry (Edgmont)200743565820805912
   PubMedGoogle Scholar
• PacchiarottiIBondDJBaldessariniRJThe International Society of Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disordersAm J Psychiatry201370111249126224030475
   PubMedGoogle Scholar
• GijsmanHJGeddesJRRendellJMNolenWAGoodwinGMAntidepressants for bipolar depression: a systematic review of randomized, controlled trialsAm J Psychiatry200416191537154715337640
   PubMed Web of Science ®Google Scholar
• El-MallakhRSKarippotAChronic depression in bipolar disorderAm J Psychiatry200616381137134116816215
   PubMed Web of Science ®Google Scholar
• AmsterdamJEfficacy and safety of venlafaxine in the treatment of bipolar II major depressive episodeJ Clin Psychopharmacol19981854144179790160
   PubMed Web of Science ®Google Scholar
• AmsterdamJDGarcia-EspañaFFawcettJEfficacy and safety of fluoxetine in treating bipolar II major depressive episodeJ Clin Psychopharmacol19981864354409864074
   PubMed Web of Science ®Google Scholar
• TohenMVietaECalabreseJEfficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depressionArch Gen Psychiatry200360111079108814609883
   PubMed Web of Science ®Google Scholar
• NemeroffCBEvansDLGyulaiLDouble-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depressionAm J Psychiatry2001158690691211384898
   PubMed Web of Science ®Google Scholar
• El-MallakhRSAdjunctive antidepressant treatment for bipolar depressionN Engl J Med2007357661517691128
   PubMedGoogle Scholar
• SachsGSNierenbergAACalabreseJREffectiveness of adjunctive antidepressant treatment for bipolar depressionN Engl J Med2007356171711172217392295
   PubMed Web of Science ®Google Scholar
• WehrTAGoodwinFKCan antidepressants cause mania and worsen the course of affective illness?Am J Psychiatry198714411140314113314536
   PubMed Web of Science ®Google Scholar
• El-MallakhRSGhaemiSNSagduyuKAntidepressant-Associated Chronic Irritable Dysphoria (ACID) in STEP-BD PatientsJ Affect Disord20081112–337237718565592
   PubMed Web of Science ®Google Scholar
• GhaemiSNOstacherMMEl-MallakhRSAntidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safetyJ Clin Psychiatry201071437238020409444
   PubMed Web of Science ®Google Scholar
• SchroederEGaoYRobertsRJEl-MallakhRSRecognition and management of bipolar depressionJ Clin Outcomes Manag20111811515525
   Google Scholar
• CruzNSanchez-MorenoJTorresFGoikoleaJMValentiMVietaEEfficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysisInt J Neuropsychopharmacol201013151419638254
   PubMed Web of Science ®Google Scholar
• DeFruytJDeshepperEAudenaertKSecond generation antipsychotic in the treatment of bipolar depression: a systematic review and meta-analysisJ Psychopharmacology2012265603617
   PubMed Web of Science ®Google Scholar
• NakamuraMOgasaMSGuarinoJLurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trialJ Clin Psychiatry200970682983619497249
   PubMed Web of Science ®Google Scholar
• NasrallahHASilvaRPhillipsDLurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled studyJ Psychiatr Res201347567067723421963
   PubMed Web of Science ®Google Scholar
• LoebelACucchiaroJSilvaRLurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled studyAm J Psychiatry2014171216016824170180
   PubMed Web of Science ®Google Scholar
• LoebelACucchiaroJSilvaRLurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: A randomized, double-blind, placebo-controlled studyAm J Psychiatry2014171216917724170221
   PubMed Web of Science ®Google Scholar
• PreskornSEreshefskyLChiuY-YPoolaNLoebelAEffect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studiesHum Psychopharmacol201328549550524014143
   PubMed Web of Science ®Google Scholar
• HamelinBAAllardSLaplanteLThe effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidonePharmacotherapy19981819159469675
   PubMed Web of Science ®Google Scholar
• GandelmanKAldermanJAGluePThe impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trialJ Clin Psychiatry2009701586219026256
   PubMed Web of Science ®Google Scholar
• MeyerJMLoebelADSchweizerELurasidone: a new drug in development for schizophreniaExpert Opin Investig Drugs2009181117151726
   PubMed Web of Science ®Google Scholar
• IshibashiTHorisawaTTokudaKPharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activityJ Pharmacol Exp Ther2010334117118120404009
   PubMed Web of Science ®Google Scholar
• UhidaHTakeuchiHGraff-GuerreroASuzukiTWatanabeKMamoDCDopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysisJ Clin Psychopharmacol201131449750221694629
   PubMed Web of Science ®Google Scholar
• WongDFKuwabaraHBrašićJRDetermination of dopamine D2 receptor occupancy by lurasidone using positron emission tomography in healthy male subjectsPsychopharmacology (Berl)2013229224525223649882
   PubMed Web of Science ®Google Scholar
• PotkinSGKeatorDBKesler-WestMLD2 receptor occupancy following lurasidone treatment in patients with schizophrenia and schizoaffective disorderCNS Spectr201419217618124073841
   PubMed Web of Science ®Google Scholar
• HedlundPBHuitron-ResendizSHenriksenSJSutcliffeJG5-HT7 receptor inhibition and inactivation induce antidepressant like behavior and sleep patternBiol Psychiatry2005581083183716018977
   PubMed Web of Science ®Google Scholar
• WesolowskaANikiforukAStachowiczKTatarczynskaEEffect of the selective-5HT7 receptor antagonist SB 269970 in animal models of anxiety and depressionNeuropharmacology200651357858616828124
   PubMed Web of Science ®Google Scholar
• BonaventurePDugovicCKramerMTranslational evaluation of JNJ-18038683, a 5-HT7 receptor antagonist, on REM sleep and in major depressive disorderJ Pharmacol Exp Ther2012342242944022570363
   PubMed Web of Science ®Google Scholar
• BonaventurePKellyLAluisioLSelective blockade of 5-hydroxytryptamine 5HT7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodentsJ Pharmacol Exp Ther2007321269069817314195
   PubMed Web of Science ®Google Scholar
• CatesLNRobertsAJHuitron-ResendizSHedlundPBEffects of lurasidone in behavioral models of depression. Role of the 5-HT7 receptor subtypeNeuropharmacology20137021121723416039
   PubMed Web of Science ®Google Scholar
• HuangMHoriguchiMFelixARMeltzerHY5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine effluxNeuroreport201223743644022415605
   PubMed Web of Science ®Google Scholar
• HuangMPanosJJKwonSOyamadaYRajagopalLMeltzerHYComparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin 5HT2A and DA D2 antagonism and 5-HT1A partial agonismJ Neurochem2014128693894924164459
   PubMed Web of Science ®Google Scholar
• MeltzerHYMasseyBWThe role of serotonin receptors in the action of atypical antipsychotic drugsCurr Opin Pharmacol2011111596721420906
   PubMed Web of Science ®Google Scholar
• HorisawaTIshibashiTNishikawaHThe effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidoneBehav Brain Res20112201839021277905
   PubMed Web of Science ®Google Scholar
• HorisawaTNishikawaHTomaSThe role of 5-HT7 receptor antagonism in the amelioration of MK-801-induced learning and memory deficits by the novel atypical antipsychotic drug lurasidoneBehav Brain Res2013244666923376699
   PubMed Web of Science ®Google Scholar
• YuenEYLiXWeiJHoriguchiMMeltzerHYYanZThe novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responsesMol Pharmacol201281211311922072817
   PubMed Web of Science ®Google Scholar
• FumagalliFCalabreseFLuoniABolisFRacagniGRivaMAModulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stressInt J Neuropscyhophramcol2012152235246
   PubMed Web of Science ®Google Scholar
• LuoniABerryACalabreseFDelayed BDNF alterations in the prefrontal cortex of rats exposed to prenatal stress: preventive effect of lurasidone treatment during adolescenceEur Neuropsychopharmacol201424698699524440552
   PubMed Web of Science ®Google Scholar
• CastrénERantamäkiTThe role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticityDev Neurobiol201070528929720186711
   PubMed Web of Science ®Google Scholar
• Sunovion Pharmaceuticals IncThe US Food and Drug Administration approved Latuda^® (lurasidone HCl) for the treatment of adult patients with depressive episodes associated with bipolar I disorder (bipolar depression), both as monotherapy and as an adjunct to lithium or valproate6282013 Available from: http://www.sunovion.com/news/latuda-press-room.htmlAccessed July 4, 2014
   Google Scholar
• Latuda^® (lurasidone HCI tablets) [prescribing information]Sunovion Pharmaceuticals Inc2013
   Google Scholar
• MeltzerHYCucchiaroJSilvaRLurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo-and-olanzapine-controlled studyAm J Psychiatry2011168995796721676992
   PubMed Web of Science ®Google Scholar
• CitromeLLurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychoticInt J Clin Pract201165218921021129135
   PubMed Web of Science ®Google Scholar
• CitromeLKetterTACucchiaroJLoebelAClinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmedJ Affect Disord2014155202724246116
   PubMed Web of Science ®Google Scholar
• De HertMYuWDetrauxJSweersKvan WinkelRCorrellCUBody weight and metabolic adverse effects of asenapine, iloperidone, lurasidone, and paliperidone in the treatment of schizophrenia and bipolar disorderCNS Drugs201226973375922900950
   PubMed Web of Science ®Google Scholar
• HowlandRHUpdate on newer antipsychotic drugsJ Psychosoc Nurs Ment Health Serv20114941315
   Web of Science ®Google Scholar
• RadoJJanicakPGPharmacological and clinical profile of recently approved second-generation antipsychoticsDrugs Aging2012291078379123018584
   PubMed Web of Science ®Google Scholar